Shanghai Celgen Biopharma Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 5

Shanghai Celgen Biopharma General Information

Description

Developer of drugs focused on treatment for autoimmune diseases and tumors. The company's products are mainly recominant protein and monoclonal antibody biologic drugs, improving the patients' health conditions.

Contact Information

Website
www.celgenpharm.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • No. 200 Chunxiao Road
  • Zhangjiang Park, Pudong District
  • Shanghai, 201203
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • No. 200 Chunxiao Road
  • Zhangjiang Park, Pudong District
  • Shanghai, 201203
  • China
+86 021

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shanghai Celgen Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC Completed Generating Revenue
6. Later Stage VC (Series B) 27-Jun-2013 Completed Generating Revenue
5. Secondary Transaction - Private 23-Jan-2013 Completed Generating Revenue
4. Later Stage VC 01-Jan-2011 Completed Generating Revenue
3. Later Stage VC 01-Mar-2010 Completed Clinical Trials - General
2. Corporate 01-Aug-2009 Completed Clinical Trials - General
1. Later Stage VC (Series A) 01-Jun-2009 Completed Clinical Trials - General
To view Shanghai Celgen Biopharma’s complete valuation and funding history, request access »

Shanghai Celgen Biopharma Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

Shanghai Celgen Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4406970-A1 Monoclonal antibody targeting tigit Pending 22-Sep-2021
EP-4393954-A1 Anti-tnfr2 monoclonal antibody and application thereof Pending 22-Sep-2021
US-20240392024-A1 Anti-tnfr2 monoclonal antibody and application thereof Pending 22-Sep-2021
US-20240400680-A1 Fusion protein of anti-tigit antibody and il2 or variant thereof and application thereof Pending 22-Sep-2021
EP-4306545-A1 Fusion protein of tnfr2 and april baff receptor Pending 12-Mar-2021 C07K14/7151
To view Shanghai Celgen Biopharma’s complete patent history, request access »

Shanghai Celgen Biopharma Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
CDH Investments PE/Buyout Minority
Chengshu Capital Venture Capital Minority
Shenzhen Capital Group Venture Capital Minority
Yuhua Capital Venture Capital Minority
Hyfinity Investments Venture Capital Minority
To view Shanghai Celgen Biopharma’s complete investors history, request access »

Ready to get started?

Request a free trial

Shanghai Celgen Biopharma FAQs

  • When was Shanghai Celgen Biopharma founded?

    Shanghai Celgen Biopharma was founded in 2000.

  • Where is Shanghai Celgen Biopharma headquartered?

    Shanghai Celgen Biopharma is headquartered in Shanghai, China.

  • What industry is Shanghai Celgen Biopharma in?

    Shanghai Celgen Biopharma’s primary industry is Drug Discovery.

  • Is Shanghai Celgen Biopharma a private or public company?

    Shanghai Celgen Biopharma is a Private company.

  • What is Shanghai Celgen Biopharma’s current revenue?

    The current revenue for Shanghai Celgen Biopharma is .

  • How much funding has Shanghai Celgen Biopharma raised over time?

    Shanghai Celgen Biopharma has raised $24M.

  • Who are Shanghai Celgen Biopharma’s investors?

    CDH Investments, Chengshu Capital, Shenzhen Capital Group, Yuhua Capital, and Hyfinity Investments have invested in Shanghai Celgen Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »